Abstract:Purinergic signaling was proposed in 1972, after it was demonstrated that adenosine 5'-triphosphate (ATP) was a transmitter in nonadrenergic, noncholinergic inhibitory nerves supplying the guinea-pig taenia coli. Later, ATP was identified as an excitatory cotransmitter in sympathetic and parasympathetic nerves, and it is now apparent that ATP acts as a cotransmitter in most, if not all, nerves in both the peripheral nervous system and central nervous system (CNS). ATP acts as a short-term signaling molecule in neurotransmission, neuromodulation, and neurosecretion. It also has potent, long-term (trophic) roles in cell proliferation, differentiation, and death in development and regeneration. Receptors to purines and pyrimidines have been cloned and characterized: P1 adenosine receptors (with four subtypes), P2X ionotropic nucleotide receptors (seven subtypes) and P2Y metabotropic nucleotide receptors (eight subtypes). ATP is released from different cell types by mechanical deformation, and after release, it is rapidly broken down by ectonucleotidases. Purinergic receptors were expressed early in evolution and are widely distributed on many different nonneuronal cell types as well as neurons. Purinergic signaling is involved in embryonic development and in the activities of stem cells. There is a growing understanding about the pathophysiology of purinergic signaling and there are therapeutic developments for a variety of diseases, including stroke and thrombosis, osteoporosis, pain, chronic cough, kidney failure, bladder incontinence, cystic fibrosis, dry eye, cancer, and disorders of the CNS, including Alzheimer's, Parkinson's. and Huntington's disease, multiple sclerosis, epilepsy, migraine, and neuropsychiatric and mood disorders.

Purinergic signalling and immune cells

Purinergic regulation of the immune system

Introduction to Purinergic Signaling

Purinergic Regulation of Neutrophil Function

Purine and purinergic receptors

Purinergic Signaling in Pulmonary Inflammation

Blood cells: an historical account of the roles of purinergic signalling

Cardiac purinergic signalling in health and disease

Purinergic enzymes on extracellular vesicles: immune modulation on the go

Purinergic signalling in endocrine organs

Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities

Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death

Historical review: ATP as a neurotransmitter

Editorial - Purinergic signalling: 50 years

Purinergic signalling in the liver in health and disease

Purinergic signalling during development and ageing

The Purinergic Agonists Atp and Utp Act Predominantly Via P2y Receptors in Human Vascular Endothelial Cells

Purine and purinergic receptors in health and disease

From purines to purinergic signalling: molecular functions and human diseases

Role of purinoreceptors in the release of extracellular vesicles and consequences on immune response and cancer progression

Purinergic P2Y2 receptors mediate rapid Ca2+ mobilization, membrane hyperpolarization and nitric oxide production in human vascular endothelial cells